Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
441.30
-2.10 (-0.47%)
At close: Jun 27, 2025, 4:00 PM
445.00
+3.70 (0.84%)
After-hours: Jun 27, 2025, 7:29 PM EDT
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,100 employees as of December 31, 2024. The number of employees increased by 700 or 12.96% compared to the previous year.
Employees
6,100
Change (1Y)
700
Growth (1Y)
12.96%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
113.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6,100 | 700 | 12.96% |
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | 3,000 | 500 | 20.00% |
Dec 31, 2018 | 2,500 | 200 | 8.70% |
Dec 31, 2017 | 2,300 | 150 | 6.98% |
Dec 31, 2016 | 2,150 | 200 | 10.26% |
Dec 31, 2015 | 1,950 | 120 | 6.56% |
Dec 31, 2014 | 1,830 | 30 | 1.67% |
Dec 31, 2013 | 1,800 | -400 | -18.18% |
Dec 31, 2012 | 2,200 | 200 | 10.00% |
Dec 31, 2011 | 2,000 | 309 | 18.27% |
Dec 31, 2010 | 1,691 | 259 | 18.09% |
Dec 31, 2009 | 1,432 | 99 | 7.43% |
Dec 31, 2008 | 1,333 | 183 | 15.91% |
Dec 31, 2007 | 1,150 | 188 | 19.54% |
Dec 31, 2006 | 962 | 149 | 18.33% |
Dec 31, 2005 | 813 | 77 | 10.46% |
Dec 31, 2004 | 736 | 12 | 1.66% |
Dec 31, 2003 | 724 | -256 | -26.12% |
Dec 31, 2002 | 980 | -20 | -2.00% |
Dec 31, 2001 | 1,000 | 545 | 119.78% |
Dec 31, 2000 | 455 | 102 | 28.90% |
Dec 31, 1999 | 353 | 13 | 3.82% |
Dec 31, 1998 | 340 | 120 | 54.55% |
Dec 31, 1997 | 220 | 42 | 23.60% |
Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VRTX News
- 6 days ago - Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Business Wire
- 6 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript - Seeking Alpha
- 8 days ago - Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions - Business Wire
- 18 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 22 days ago - Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Business Wire
- 4 weeks ago - Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? - Seeking Alpha
- 6 weeks ago - Vertex to Participate in Upcoming Investor Conferences - Business Wire